Cellectis To Host Conference Call And Webcast On September 14 To Provide A Business Update
Conference Call and Webcast Details:
September 14, 2026
- English-language at 8:00 a.m. ET. / 2:00 p.m. CET
Webcast link:
Phone number: +1 (800) 717 1738 or +1 (646) 307 1865
France Toll Free: +33 (800) 945 120
- French-language at 9:00 a.m. ET. / 3:00 p.m. CET
Webcast link:
Phone number: +1 (800) 717 1738 or +1 (646) 307 1865
France Toll Free: +33 (800) 945 120
A replay will be available on the Company's website following the event.
About Cellectis
Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company utilizes an allogeneic approach for CAR T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to develop gene therapies in other therapeutic indications. With its in-house manufacturing capabilities, Cellectis is one of the few end-to-end gene editing companies that controls the cell and gene therapy value chain from start to finish. Cellectis' headquarters are in Paris, France, with locations in New York and Raleigh, NC. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find out more, visit and follow Cellectis on LinkedIn and X.
For further information on Cellectis, please contact:
Media contacts:
Pascalyne Wilson, Director, Communications, + 33 (0)7 76 99 14 33,
Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93, ...
Investor Relations contact:
Arthur Stril, Chief Financial Officer & Chief Business Officer, ...
Attachment
- PRESS RELEASE_conference call_ENGLISH
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment